Dr. Nouha Setti Boubaker is a postdoctoral researcher at the Laboratory of Protein Engineering and Bioactive Molecules (LIP-MB), INSAT, University of Carthage, and a clinical research associate in the Department of Urology at Charles Nicolle Hospital, Tunis. Her research bridges molecular biology and clinical oncology, with a focus on translational studies in non-muscle-invasive bladder cancer (NMIBC) and the identification of predictive molecular and immune-inflammatory biomarkers of treatment response. She holds a PhD in Biological Engineering from INSAT, with training in molecular pathology, liquid biopsy, cancer biology, and tumor immunology. Her expertise includes miRNA profiling, immune-inflammatory indices (NLR, MLR, PLR, SII, SIRI), and the integration of clinical and transcriptomic data (RNA-seq) with machine learning to develop prognostic models and explore drug repurposing for bladder and prostate cancers and and Upper Tract Urothelial carcinoma. She has contributed to multiple national and international collaborations, including a visiting research fellowship (2017–2018) at the IRCCS Regina Elena National Cancer Institute, Rome, focused on genomic profiling and miRNA-based biomarker discovery. She was an active member of the Italian Association of Cell Biology and Differentiation (ABCD, 2017–2019) and engaged in molecular oncology consortia. In 2022–2023, she received the prestigious Fondazione Umberto Veronesi Postdoctoral Fellowship (Milan, Italy), leading projects on ATM missense variants using CRISPR/Cas9 knock-in cell models to advance precision oncology. Building on her dual affiliation with INSAT and Charles Nicolle Hospital, she has recently secured a national collaborative project (PRC) from the Tunisian Ministry of Higher Education and Scientific Research, conducted with the Pasteur Institute of Tunis, investigating therapy resistance in urogenital cancers and developing novel personalized strategies for improved patient management.